|Table of Contents|

Expression and clinical significance of AP2S1 in bladder cancer tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2284-2288
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of AP2S1 in bladder cancer tissues
Author(s):
WANG Ming1; ZHANG Yan2; WANG Chaoqi1
1.Affiliated Hospital of Inner Mongolia Minzu University,Inner Mongolia Tongliao 028007,China;2.People's Hospital of Tongliao,Inner Mongolia Tongliao 028007,China.
Keywords:
bladder urothelial carcinoma; AP2S1; immunohistochemistry
PACS:
R734.14
DOI:
10.3969/j.issn.1672-4992.2023.12.019
Abstract:
Objective:To investigate the expression and clinical significance of adaptor-related protein complex 2，sigma 1 subunit（AP2S1) in bladder carcinoma tissues.Methods:At the data mining part，the mutated and amplified genes of the TCGA-BLCA data set were downloaded from the cbioportal website（https://www.cbioportal.org/).The relationships between AP2S1 expression and clinicopathological parameters and prognosis of patients with BLCA were retrospectively analyzed.Results:Immunohistochemistry results showed that the expression of AP2S1 in bladder cancer tissue was significantly higher than that in normal bladder tissues（P<0.05).The positive expression rate of AP2S1 in bladder cancer tissues was 72.9%（70/96)，while the positive expression rate of AP2S1 in adjacent normal tissues was 25.0%（7/28).The results of clinical sample analysis showed that the size，clinical stage，pathological grade，and recurrence of bladder tumor were correlation with the expression of AP2S1.There was no correlation between the gender，age,lymphatic vascular infiltration and the expression of AP2S1.The positive expression rates of AP2S1 in<3 cm subgroup and ≥3 cm subgroup were 60.00%（24/40) and 82.14%(46/56) respectively.The positive expression rate of AP2S1 was 67.14%(47/70) in ≤T1 subgroup and 88.46%(23/26) in ≥T2 subgroup.The positive expression rate was 81.82%（45/55) in the high-grade group and 60.98%（25/41) in the low-grade group.The positive expression rate was 70.13%（54/77) in the group without lymphatic vascular invasion and 84.21%（16/19) in the group with lymph vessel invasion.The positive expression rate was 60.00%(24/40) in the group without disease recurrence and 82.14%(46/56) in the group with disease recurrence.Conclusion:AP2S1 was highly expressed in BLCA tissue,which may be closely related to clinical stage,pathological grade,tumor size and disease recurrence,and was expected to become a therapeutic target for bladder cancer.

References:

［1］FERLAY J，STELIAROVA-FOUCHER E，LORTET-TIEULENT J，et al.Cancer incidence and mortality patterns in Europe：estimates for 40 countries in 2012［J］.Eur J Cancer，2013,49(6)：1374-1403.
［2］FERLAY J，SOERJOMATARAM I，DIKSHIT R，et al.Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012［J］.Int J Cancer，2015,136(5)：E359-E386.
［3］POWLES T，ROSENBERG JE，SONPAVDE GP，et al.Enfortumab vedotin in previously treated advanced urothelial carcinoma［J］.N Engl J Med，2021,384(12)：1125-1135.
［4］BALAR AV，CASTELLANO D，O'DONNELL PH，et al.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer(KEYNOTE-052):a multicentre，single-arm，phase 2 study［J］.Lancet Oncol，2017,18(11):1483-1492.
［5］VUKY J，BALAR AV，CASTELLANO D，et al.Long-term outcomes in KEYNOTE-052:Phase Ⅱ study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer［J］.J Clin Oncol，2020,38(23):2658-2666.
［6］BALAR AV，GALSKY MD，ROSENBERG JE，et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma:a single-arm，multicentre， phase 2 trial［J］.Lancet，2017,389(10064):67-76.
［7］COLLINS BM，MCCOY AJ，KENT HM，et al.Molecular architecture and functional model of the endocytic AP2 complex［J］.Cell，2002,109(4):523-535.
［8］HANNAN FM，STEVENSON M，BAYLISS AL，et al.Ap2s1 mutation causes hypercalcaemia in mice and impairs interaction between calcium-sensing receptor and adaptor protein-2［J］.Hum Mol Genet，2021,30(10):880-892.
［9］NESBIT MA，HANNAN FM，HOWLES SA，et al.Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3［J］.Nat Genet，2013,45(1):93-97.
［10］HOWLES SA，HANNAN FM，BABINSKY VN，et al.Cinacalcet for symptomatic hypercalcemia caused by AP2S1 mutations［J］.N Engl J Med，2016,374(14):1396-1398.
［11］LI T，FU J，ZENG Z，et al.TIMER2.0 for analysis of tumor-infiltrating immune cells［J］.Nucleic Acids Res，2020,48(W1):W509-W514.
［12］JANSSEN G，RAMKUMAR RR，LEE BH，et al.Orthotopic urinary diversions after radical cystectomy for bladder cancer:lessons learned last decade［J］.Curr Opin Urol，2021,31(6):580-585.
［13］GAKIS G，EFSTATHIOU J，LERNER SP，et al.ICUD-EAU international consultation on bladder cancer 2012:Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder［J］.Eur Urol，2013,63(1):45-57.
［14］YENERALL P，DAS AK，WANG S，et al.RUVBL1/RUVBL2 ATPase activity drives PAQosome maturation，DNA replication and radioresistance in lung cancer［J］.Cell Chem Biol，2020,27(1):105-121.
［15］NG K，STENZL A，SHARMA A，et al.Urinary biomarkers in bladder cancer:A review of the current landscape and future directions［J］.Urol Oncol，2021,39(1):41-51.

Memo

Memo:
内蒙古自治区自然科学基金项目(编号:2021MS08071);内蒙古自治区卫生和计划生育委员会医疗卫生科研计划(编号：202202264)；内蒙古自治区直属高校基本科研业务费项目（编号：43）
Last Update: 1900-01-01